Chester County News and Community Website
BERWYN, PA — Chester County-based biotech company, Panavance Therapeutics Inc., has announced the recent publication of positive data in the International Journal of Molecular Sciences about the anti-tumor activity of …
Panavance Therapeutics’ Cancer Drug Misetionamide Shows Promising Results in Melanoma Treatment Read More BERWYN, PA — Panavance Therapeutics Inc. announced it will present at the BIO Investor Forum on Tuesday, October 17 at 10 a.m. PT.
Panavance to Present at the BIO Investor Forum Read More BERWYN, PA — Panavance Therapeutics Inc. announced the recent publication of positive data in the peer-reviewed Journal of Cellular and Molecular Medicine in a manuscript titled, “GP-2250, a novel anticancer agent, …
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer Read More BERWYN, PA — Panavance Therapeutics Inc., a clinical-stage pharmaceutical company, announced that Greg Bosch, Chairman and CEO, James Costin, M.D., Head of Research & Development, José Iglesias, M.D., Chief Medical Officer, and Ben …
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series Read More BERWYN, PA — Panavance Therapeutics Inc., a clinical-stage pharmaceutical company, announced the recent publication of positive preliminary data in a manuscript titled, “The effect of GP‑2250 on cultured virus‑negative Merkel …
Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC) Read More BERWYN, PA — Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, June 6, 2023, at 4:15 PM ET in Room 103 …
Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention Read More BERWYN, PA — Panavance Therapeutics Inc. recently announced that positive data from the Company’s tumor cell selective and broadly active small molecule with a unique mechanism of action, GP-2250 (misetionamide), was …
Breakthrough Oncology Drug Shows Promising Results Read More BERWYN, PA — Panavance Therapeutics Inc. recently announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present at BioNJ’s Thirteenth Annual BioPartnering Conference on Tuesday, April 18, 2023, at 10:20 …
Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference Read More